116 related articles for article (PubMed ID: 17970033)
1. New approach to cancer therapy: heparin binding-epidermal growth factor-like growth factor as a novel targeting molecule.
Miyamoto S; Yagi H; Yotsumoto F; Horiuchi S; Yoshizato T; Kawarabayashi T; Kuroki M; Mekada E
Anticancer Res; 2007; 27(6A):3713-21. PubMed ID: 17970033
[TBL] [Abstract][Full Text] [Related]
2. Cross-reacting material 197, a heparin-binding EGF-like growth factor inhibitor, reverses the chemoresistance in human cisplatin-resistant ovarian cancer.
Tang XH; Li M; Deng S; Lu MS
Anticancer Drugs; 2014 Nov; 25(10):1201-10. PubMed ID: 25115341
[TBL] [Abstract][Full Text] [Related]
3. The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer.
Tang XH; Deng S; Li M; Lu MS
Biochem Biophys Res Commun; 2012 Jun; 422(4):676-80. PubMed ID: 22609777
[TBL] [Abstract][Full Text] [Related]
4. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract][Full Text] [Related]
5. Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition.
Yagi H; Yotsumoto F; Miyamoto S
Mol Cancer Ther; 2008 Oct; 7(10):3441-51. PubMed ID: 18852147
[TBL] [Abstract][Full Text] [Related]
6. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy.
Miyamoto S; Hirata M; Yamazaki A; Kageyama T; Hasuwa H; Mizushima H; Tanaka Y; Yagi H; Sonoda K; Kai M; Kanoh H; Nakano H; Mekada E
Cancer Res; 2004 Aug; 64(16):5720-7. PubMed ID: 15313912
[TBL] [Abstract][Full Text] [Related]
7. Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy.
Miyamoto S; Yagi H; Yotsumoto F; Kawarabayashi T; Mekada E
Cancer Sci; 2006 May; 97(5):341-7. PubMed ID: 16630129
[TBL] [Abstract][Full Text] [Related]
8. Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy.
Tsujioka H; Yotsumoto F; Hikita S; Ueda T; Kuroki M; Miyamoto S
Curr Opin Obstet Gynecol; 2011 Feb; 23(1):24-30. PubMed ID: 20966750
[TBL] [Abstract][Full Text] [Related]
9. Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer.
Tang XH; Deng S; Li M; Lu MS
Tumour Biol; 2016 Apr; 37(4):5521-8. PubMed ID: 26572150
[TBL] [Abstract][Full Text] [Related]
10. Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer.
Yagi H; Yotsumoto F; Sonoda K; Kuroki M; Mekada E; Miyamoto S
Int J Cancer; 2009 Mar; 124(6):1429-39. PubMed ID: 19048624
[TBL] [Abstract][Full Text] [Related]
11. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
Tang XH; Lu MS; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
[No Abstract] [Full Text] [Related]
12. [Role and mechanism of the regulation of nuclear factor-κB by heparin binding-epidermal growth factor-like growth factor in the induction of paclitaxel resistance of ovarian cancer].
Tang XH; Lu MS; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2019 Apr; 54(4):255-261. PubMed ID: 31006192
[No Abstract] [Full Text] [Related]
13. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer.
Tanaka Y; Miyamoto S; Suzuki SO; Oki E; Yagi H; Sonoda K; Yamazaki A; Mizushima H; Maehara Y; Mekada E; Nakano H
Clin Cancer Res; 2005 Jul; 11(13):4783-92. PubMed ID: 16000575
[TBL] [Abstract][Full Text] [Related]
14. [HB-EGF is a promising target molecule for ovarian cancer].
Miyamoto S; Yagi H; Tanaka Y
Fukuoka Igaku Zasshi; 2004 Nov; 95(11):286-90. PubMed ID: 15717494
[No Abstract] [Full Text] [Related]
15. Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance.
Wang F; Liu R; Lee SW; Sloss CM; Couget J; Cusack JC
Oncogene; 2007 Mar; 26(14):2006-16. PubMed ID: 17001310
[TBL] [Abstract][Full Text] [Related]
16. Pre-clinical study of BK-UM, a novel inhibitor of HB-EGF, for ovarian cancer therapy.
Nam SO; Yotsumoto F; Miyata K; Suzaki Y; Yagi H; Odawara T; Manabe S; Ishikawa T; Kuroki M; Mekada E; Miyamoto S
Anticancer Res; 2014 Aug; 34(8):4615-20. PubMed ID: 25075108
[TBL] [Abstract][Full Text] [Related]
17. Heparin-Binding Epidermal Growth Factor-Like Growth Factor as a Potent Target for Breast Cancer Therapy.
Lian C; Ruan L; Shang D; Wu Y; Lu Y; Lü P; Yang Y; Wei Y; Dong X; Ren D; Chen K; Liu H; Tu Z
Cancer Biother Radiopharm; 2016 Apr; 31(3):85-90. PubMed ID: 27093342
[TBL] [Abstract][Full Text] [Related]
18. [Heparin-binding epidermal growth factor (HB-EGF): myth or reality?].
Scuderi R; Failla A
Clin Ter; 2008; 159(2):111-6. PubMed ID: 18463770
[TBL] [Abstract][Full Text] [Related]
19. HB-EGF Is a Promising Therapeutic Target for Lung Cancer with Secondary Mutation of
Yotsumoto F; Fukagawa S; Miyata K; Nam SO; Katsuda T; Miyahara D; Odawara T; Manabe S; Ishikawa T; Yasunaga S; Miyamoto S
Anticancer Res; 2017 Jul; 37(7):3825-3831. PubMed ID: 28668882
[TBL] [Abstract][Full Text] [Related]
20. The EGFR ligands amphiregulin and heparin-binding egf-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer.
Yasumoto K; Yamada T; Kawashima A; Wang W; Li Q; Donev IS; Tacheuchi S; Mouri H; Yamashita K; Ohtsubo K; Yano S
Clin Cancer Res; 2011 Jun; 17(11):3619-30. PubMed ID: 21482691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
